Prenetics Global Limited

NASDAQ:PRE

Medical - Diagnostics & Research

Healthcare
$10.35 +2.19%

+$0.43 today

Market cap
$185.61M
Beta
0.24
P/E (TTM)
-4.9
EPS (TTM)
-$4.18
52W Low $7.18High $23.63

Volume 1.58M

Average 0.22M

PRE Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Prenetics Global LimitedNASDAQ: PRE

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $31.55M rose 98.8% year over year, ahead of the +58.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 10.4% from the prior quarter. Over 3 fiscal years it compounded at +7.6% a year.

Context

  • Selling, general & admin amounted to 86.4% of revenue in FY2025, down 94.4 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $632.31M (+692.4%) for the fiscal year ending Dec 2026, a step up from the +44.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.55M+10.4% QoQ
Last fiscal yearDec 2025
$79.8M+44.1% YoY
LTMMar 2026
$95.47M+58.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+98.8%+782.0%+683.2 pp
1 year+44.1%+692.4%+648.3 pp
3-year CAGR+7.6%+165.9%+158.3 pp
5-year CAGR+94.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
79.8M USD
Year-over-year change
+44.1%
4-year CAGR
+10.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How PRE compares with its peers on the latest reported figures

  • PRE's LTM Mar 2026 selling, general & admin of $95.47M is the 2nd highest of the 11 companies compared; the peer median is $42.97M.
  • Its year-over-year change of +58.4% is the highest of 11, against a peer median of -3.6%.
  • Selling, general & admin amounts to 83.9% of revenue for PRE, versus a peer median of 103.0%.
PRE Competitors Peer median
Selling, General & Admin for PRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STIMNeuronetics, Inc.LTM Mar 2026$95.81M +14.8%+8.8%63.2%
PREPrenetics Global LimitedLTM Mar 2026$95.47M +58.4%+7.6%83.9%
ATLNAtlantic International Corp.LTM Dec 2025$91.29M +42.6%+29.3%20.9%
OSUROraSure Technologies, Inc.LTM Mar 2026$74.99M -2.4%-14.3%66.4%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$51.33M +16.1%+25.8%114.4%
CDXSCodexis, Inc.LTM Mar 2026$43.75M -19.9%-3.4%56.0%
MXCTMaxCyte, Inc.LTM Mar 2026$42.18M -24.8%+1.9%130.7%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$31.65M -26.4%-17.7%91.6%
PROFProfound Medical Corp.LTM Mar 2026$30.61M -29.9%+22.1%162.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.81M +22.1%-7.6%914.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$12.62M -4.8%+18.6%426.6%
Peer median (excluding PRE) $42.97M-3.6%+5.3%103.0%

Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.53M13.16M21.74M30.62M92.39M
Cost of Revenue8.93M9.55M12.91M15.22M43.6M
Gross Profit3.6M3.62M8.83M15.4M48.79M
Gross Margin28.7%27.5%40.6%50.3%52.8%
Research & Development6.39M5.99M11.66M10.92M5.13M
Selling, General & Admin53.67M64.08M49.68M55.37M79.8M
Operating Expenses60.26M69.64M60.74M63.54M86.92M
Depreciation & Amortization7.35M7.54M7.79M5.93M3.78M
EBITDA(209.16M)(218.04M)(47.9M)(51.57M)(32.19M)
EBITDA Margin-1668.9%-1656.3%-220.3%-168.4%-34.8%
Operating Income(56.66M)(66.02M)(51.91M)(48.14M)(38.13M)
Operating Margin-452.1%-501.5%-238.7%-157.2%-41.3%
Interest Income201472K3.92M2.04M1.04M
Interest Expense42.23K242K119.66K203K241K
Other Income / Expenses(159.89M)(159.8M)(4.76M)(9.56M)1.92M
Income Before Tax(216.55M)(225.82M)(56.67M)(57.7M)(36.21M)
Pre-Tax Margin-1727.9%-1715.4%-260.6%-188.4%-39.2%
Income Tax Expense2.57M(245K)(269.36K)(7.87M)34K
Net Income(174.01M)(190.45M)(62.72M)(46.3M)(37.71M)
Net Margin-1388.4%-1446.8%-288.5%-151.2%-40.8%
EPS (Basic)(47.04)(37.57)(5.58)(3.64)(2.68)
EPS (Diluted)(47.04)(37.57)(5.58)(3.64)(2.68)
Weighted Avg Shares3.7M5.07M11.25M12.71M14.05M
Weighted Avg Shares (Diluted)3.7M5.07M11.25M12.71M14.05M

Prenetics Global Limited

NASDAQ:PRE

Intrinsic Alpha fair value

Locked

Current Price

$10.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.